PuraMed Bioscience Goes Social to Promote Drug for Migraine Headache Relief

Online, March 7, 2011 (Newswire.com) - (Schofield, WI) - PuraMed Bioscience, Inc. (OTCQB: PMBS) and LWI have signed a deal to provide their, Homeopathic Drug for the relief of Migraine Headache pain, LipiGesic™ M, more exposure via the social media networks. This will help put PuraMed Bioscience Inc in a position to attract more customers in the most efficient possible way. PuraMed looks to be at the forefront of modern marketing innovation in the bioscience industry by locating migraine sufferers, connecting with them and offering real, proven, safe, relief.

Migraine headaches are considered to be the most expensive brain disorder in the United States. It is estimated that up to 50 million Americans suffer from migraine headaches In addition, approximately 5% of all children in America experience recurrent headaches consistent with migraines. Currently there are no prescription drugs approved to treat adolescents.

"As we work through the final details regarding the publication of our multi-site double blind placebo controlled migraine headache study featuring LipiGesic M in a top tier medical journal and begin the retail launch of LipiGesic M, we now have the tools and the team that will allow us to reach out to the world and engage consumers who are actively seeking cost effective, proven relief from their migraine headache pain." says said Russell Mitchell, CEO, PuraMed Bioscience Inc.

"Social media marketing facilitates a conversation between the brand and the customer, thereby engaging the two parties in such a way that loyalty is solidified. More importantly, it is a way for companies like PuraMed to locate sufferers of migraines and educate them on the ways their product can help, thus driving more sales.", said Eric Rice, CEO, LWI. LWI is known for providing social media solutions to many sectors of business, one of which is the bioscience space. They have similar agreements with several other Bioscience and Life Science companies.

About the PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches; the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.

Currently, LipiGesic™ M may be purchased by calling 877-851-2190 or visiting www.mymigrainegone.com or www.lipigesic.com. The Company's two-minute direct response television commercial is available for viewing on these websites as well.

Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

For more information, contact:
Russell Mitchell, Chairman and CEO
PuraMed BioScience, Inc.
715-359-6373
Email: [email protected]
Website: www.PuramedBioScience.com

Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy, 847-945-2222

Media Contact:
North Shore Public Relations, Inc.
Renae Placinski, 847-945-4505
Email :[email protected]